CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / United Therapeutics CORP (UTHR) / ralinepag
Forward catalyst · UTHR

ralinepag

Sponsor United Therapeutics CORP · listed as UTHR

READOUT Phase 3 Confidence: medium Source: clinicaltrials

ralinepag is a drug asset sponsored by United Therapeutics CORP, listed as UTHR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT03683186. That trial is in Phase 3 and currently enrolling by invitation, studying PAH.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT03683186
PhasePHASE3
StatusENROLLING_BY_INVITATION
Lead sponsorUnited Therapeutics
Listed asUTHR
Condition(s)PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseas…
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More UTHR catalysts

Related catalysts and sponsor